Yakult Honsha Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Yakult Honsha Co. Ltd.
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
The Japanese firm has decided to shrink its oncology portfolio by transferring its rights to oxaliplatin in Japan, along with a portfolio of generics, to Takata. Though Yakult will maintain an interest in the area through irinotecan and several other anticancers, its has said future R&D investment will shift more towards the microbiome.
Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
- Medical Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.